Predictors of successful valproate withdrawal in women with epilepsy.

Atalar A. Ç., Şirin N. G., Bebek N., Baykan B.

Epilepsy & behavior : E&B, vol.119, pp.107980, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 119
  • Publication Date: 2021
  • Doi Number: 10.1016/j.yebeh.2021.107980
  • Journal Name: Epilepsy & behavior : E&B
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE, Psycinfo
  • Page Numbers: pp.107980
  • Keywords: Valproic acid, Women with epilepsy, Valproate withdrawal, Valproate switch, JUVENILE MYOCLONIC EPILEPSY, TEMPORAL-LOBE EPILEPSY, SODIUM VALPROATE, ANTIEPILEPTIC DRUGS, EYELID MYOCLONIA, ILAE COMMISSION, MONOTHERAPY, PROGNOSIS, ACID, CARBAMAZEPINE
  • Istanbul University Affiliated: Yes

Abstract

Objective: Valproate (VPA) use was restricted due to its teratogenic risks in women with epilepsy (WWE). We aimed to assess the outcome and predictors of treatment decisions of withdrawal/switch or continuation of VPA in WWE. Methods: We included 214 consecutive WWE with a follow-up time of 9.57 +/- 7.04 years, who have used (n = 142) or are still using VPA (n = 72) during their reproductive ages. The demographic, clinical, and electroencephalography (EEG) properties of WWE who could withdraw (successful withdrawal; n = 142) and could not withdraw VPA (unsuccessful withdrawal; n = 36) were compared statistically.